A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
Status:
Completed
Trial end date:
2021-05-17
Target enrollment:
Participant gender:
Summary
The study will evaluate bioavailability, pharmacokinetics, safety, and tolerability of
budesonide, glycopyrronium and formoterol (BGF) metered dose inhaler (MDI) formulated with 3
different propellants: Propellant 1 (Treatment A [test]), Propellant 2 (Treatment B [test])
and Hydrofluoroalkane (HFA) (Treatment C [reference]).